ArticleAsian journal of pharmaceutical sciences2017
A multi-functional nanoplatform for efficacy tumor theranostic applications.
Article in Asian journal of pharmaceutical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Multifunctional Hybrid MoSNanomaterials (Basel, Switzerland) · 2022Article
- MoSBioactive materials · 2021Review
- 2D Nanosheets-A New Class of Therapeutic Formulations against Cancer.Pharmaceutics · 2021Review
- Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.Acta pharmaceutica Sinica. B · 2021Review
- Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors.Asian journal of pharmaceutical sciences · 2019Article
- Biological interactions of biocompatible and water-dispersed MoSScientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials with multiple functions have become more and more popular in the domain of cancer research. MoS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.